Beijing Business Daily (Reporter Ma Changhuan) Runda Medical (603108), which is deeply involved in the “false positive” rumors of nucleic acid testing, disclosed an announcement on the morning of May 11 that it had requested its subsidiary, Zhongke Laboratory Shanghai Zhongke Runda Medical Laboratory Co., Ltd. (hereinafter referred to as “Zhongke Laboratory”) launched an internal self-examination on the nucleic acid detection work and cooperated with relevant departments in the investigation.
Runda Medical said that it was concerned about the media reports on the nucleic acid testing work of the company’s subsidiaries, which aroused market attention. Relevant reports mentioned that during the nucleic acid screening process of the company’s subsidiary, Zhongke Laboratory, in Huangpu District, Shanghai, some samples tested positive, but the test results of related cases were negative after entering the Fangcang shelter hospital. The accuracy of nucleic acid testing data of the Chinese Academy of Sciences.
Runda Medical pointed out that Zhongke Laboratory is a wholly-owned company of Shanghai Zhongke Runda Precision Medical Inspection Co., Ltd., which holds 48.43% of the company’s shares. Regarding the above public opinion, the company attaches great importance to it, and the company has requested China Science Laboratory to initiate an internal self-examination on the relevant situation and cooperate with relevant departments in the investigation.
The trading market shows that the stock price of Runda Medical fell by the limit on May 10, and finally closed down 3.96% on that day.